MedTrace Logo

Gene Therapy for the Treatment of Chronic Stable Angina

NCT01002495 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2025-09-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of catheter based injections of VM202 into the heart.

Conditions

  • Myocardial Ischemia

Interventions

BIOLOGICAL

VM202

Endocardial injections on Day 0.

Sponsors & Collaborators

  • Helixmith Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-07-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01002495 on ClinicalTrials.gov